RIGL Stock — Rigel Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$46.64

Market cap

$871.2M

Cash

$95.3M

Enterprise value

$820.9M

Balance sheet

Cash	$95.3M
Debt	$45.0M
Net cash	$50.3M
Enterprise value	$820.9M
Basic shares	19.6M shares
Fully diluted shares	24.3M shares
Fully diluted market cap	$1,132.2M
Cash per share	$4.86

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RIGL daily closes…

Loading price history…

Pipeline assets

fostamatinib

Approved · Active Modality: oral small molecule (SYK inhibitor)

Aliases fostamatinib disodium hexahydrate, TAVALISSE

Target SYK

Partnerships Grifols (exclusive commercialization license, Europe/UK/Turkey/Middle East/North Africa/Russia-CIS); Kissei (exclusive license and supply, approved in Korea Jan 2025); Medison (Canada and Israel, chronic ITP); Knight Therapeutics International (Latin America)

Indications

chronic immune thrombocytopenia (ITP) (Approved)

Status note First FDA-approved product; only approved oral SYK inhibitor for adult chronic ITP patients with insufficient response to prior treatment. Commercialized ex-US through multiple licensees.

olutasidenib

Phase 2 · Active Modality: oral small molecule (IDH1 inhibitor)

Target IDH1

Partnerships MD Anderson Cancer Center and CONNECT (development collaborations for IDH1-mutation disease areas); Kissei (exclusive development/commercialization rights in Kissei territory, Sept 2024)

Indications

relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutation (Approved)
glioma (Phase 2)

Status note Second FDA-approved product (REZLIDHIA) for adult R/R AML with susceptible IDH1 mutation. In Jan 2024 Rigel announced a collaboration with CONNECT to evaluate olutasidenib in glioma via the molecularly guided Phase 2 umbrella TarGet study (first patient enrolled Oct 2025).

R289

Phase 1 · Active Modality: small molecule inhibitor

Target IRAK1/4

Indications

lower-risk myelodysplastic syndrome (MDS), relapsed/refractory/resistant (Phase 1)

Status note Dual IRAK1/4 inhibitor in open-label Phase 1b study evaluating safety, tolerability and preliminary efficacy in patients with lower-risk MDS relapsed, refractory or resistant to prior therapy.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06445959	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Mutant IDH1 Inhibitor Olutasidenib	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for M.D. Anderson Cancer Center on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

RIGL — Rigel Pharmaceuticals Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials